- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cleveland Clinic’s 2020 Medical Innovation Summit to Focus on ‘The Future of Healthcare: Digital Transformation’
The 18th annual summit will bring together speakers and leaders with actionable insights for healthcare evolution.
Cleveland Clinic’s Medical Innovation Summit will be held virtually with complimentary registration on Tuesday, October 6, allowing participants from around the globe to join the annual event.
With a focus on the adoption of virtual care and other digital health initiatives, the one-day summit brings together speakers and leaders from organizations that span the health spectrum to deliver content to individuals looking to innovate for healthcare’s areas of opportunity.
Now in its 18th year, the Medical Innovation Summit is organized by Cleveland Clinic Innovations, the development and commercialization arm of Cleveland Clinic.
“Innovation is a core value at Cleveland Clinic that has transformed how we deliver care and inspired the Medical Innovation Summit,” said Will Morris, MD, executive medical director of Cleveland Clinic Innovations. “The summit brings together leaders from a variety of industries to share their expertise and best ideas to promote the evolution of health care.”
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
